The investment firm took a new 2.68% position in Nektar Therapeutics, reflecting confidence in its 669% year-over-year stock surge.
Patient Square Capital LP acquired 210,000 shares of Nektar Therapeutics (NKTR) for $11.96 million, according to an SEC filing dated May 15, 2026. The position, valued at $15.11 million at quarter-end, marked a new holding for the firm, representing 2.68% of its reportable assets under management.
Nektar’s stock closed at $74.33 on May 14, 2026, up 669.46% over the prior year and outperforming the S&P 500 by 642.16 percentage points. The company focuses on oncology and immunology therapies, with key candidates in clinical trials.
Patient Square’s top holdings after the filing included ROIV ($226.2 million), ARGX ($26.8 million), and INSM ($25.8 million), with NKTR now among its significant positions.